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Background: Cognitive impairment and visual deterioration are two key clinical symptoms in MS and affect 50 to
80% of patients. Little is known about the influence of cognitive impairment on visual tests recommended for MS
such as low contrast sensitivity testing. Our objective was to investigate whether low contrast sensitivity testing is
influenced by cognitive impairment in multiple sclerosis (MS) patients.
Methods: Cross-sectional study including 89 patients with relapsing-remitting MS. All patients received cognitive
evaluation using Rao’s Brief Repeatable Battery of Neuropsychological Testing (BRB-N). Visual assessments included
low contrast sensitivity (CS) by functional acuity contrast testing and high contrast visual acuity (VA) using ETDRS
charts. Retinal morphology as visual impairment correlate was measured using retinal nerve fiber layer (RNFL)
thickness by optical coherence tomography.
Results: In combined analyses using generalized estimating equation models, Paced Auditory Serial Addition Test
(PASAT) and RNFL as well as and the Symbol Digit Modalities Test (SDMT) and RNFL predicted CS. To further
control for a potential influence of the anterior visual system we performed partial correlation analyses between
visual function and cognitive function test results but controlling for RNFL. Even when controlling for RNFL, CS was
associated with PASAT performance and SDMT performance.
Conclusion: Our data show that: a) cognitive impairment and performance in visual function tests such as low
contrast sensitivity testing are associated; b) the main cognitive domains correlating with visual test performance
are information processing speed and, to a lesser degree, memory; This preliminary data needs to be substantiated
in further studies investigating patients with a higher cognitive burden, healthy controls and in longitudinal
settings.
Keywords: Multiple sclerosis, Cognition, Vision, Vision tests, Contrast sensitivity, Neuropsychological tests, Optical
coherence tomography, Retinal nerve fiber layerBackground
Multiple sclerosis (MS) is the most prevalent auto-
immune disorder of the central nervous system and pre-
sents with a variety of neurologic symptoms [1]. About
80% of patients experience visual dysfunction which is
the presenting symptom in every second patient [2].
Even in visually asymptomatic patients, subclinical visual* Correspondence: alexander.brandt@charite.de
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reproduction in any medium, provided the orsystem deficits can be detected using high-sensitivity
methods like high-pass resolution perimetry [3] or high
resolution optical coherence tomography (OCT) [4,5].
Due to the frequency of visual deficits in MS, assess-
ment of visual function plays an important role in clin-
ical trials and clinical practice [6]. Visual symptoms are
usually assessed during neurological examination with a
combination of history taking, finger-perimetric visual
field assessment and visual acuity testing using Snellen
charts [7]. However, previous studies have shown that
detection and quantification of visual dysfunction withLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overview of cohort’s clinical and visual data
RRMS
Subjects N 89
Sex Male, N (%) 36 (40)
Female, N (%) 53 (60)
Age (years) Mean ± SD 42 ± 9
Min - Max 25 - 62
Time since diagnosis
(months)
Mean ± SD 97 ± 67
Min - Max 2 - 340
EDSS Median 2.0
Min - Max 0.0 - 6.0
RNFL Average (μm) Mean ± SD 84.5 ± 14.3
Min - Max 33.2 - 117.4
VA (ETDRS Snellen
equivalents)
Mean ± SD 1.05 ± 0.36
Min - Max 0.20 - 1.60
CS (FACT AUC) Mean ± SD 1.85 ± 0.32
Min - Max 0.82 - 2.28
Cognitively impaired
(BRB-N z < 0.168)
No, N (%) 63 (72)
Yes, N (%) 25 (28)
Fatigue severity
scale (FSS)
Mean ± SD 5.0 ± 2.5
Min - Max 0.0 - 9.0
Fatigued (FSS > = 4.0) No, N (%) 35 (39)
Yes, N (%) 54 (61)
Beck’s depression
inventory (BDI)
Mean ± SD 8.1 ± 7.9
Min - Max 0 - 29
Depressed
(BDI > = 30; 19-29; 10-18; 0-9)
Minimal, N (%) 60 (69)
Mild, N (%) 14 (16)
Moderate, N (%) 13 (15)
Severe, N (%) 0 (0)
Abbreviations: EDSS expanded disability status scale, RNFL retinal nerve fibre
layer thickness, VA visual acuity, ETDRS early treatment diabetic retinopathy
study, CS contrast sensitivity, FACT functional acuity contrast testing, AUC area
under the log contrast sensitivity function, BRB-N brief repeatable battery of
neuropsychological tests.
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larly, mild changes are easily overlooked [8]. Hence, sev-
eral recent studies have investigated higher sensitivity
tools based on low contrast sensitivity testing for detect-
ing damage to the visual pathway. Here, the Sloan low
contrast visual acuity charts [6,9-11] and the Pelli-
Robson contrast sensitivity charts [10,12] have been
demonstrated as superior to high contrast visual acuity
testing in MS. Both visual outcome measures have also
been shown to correlate strongly with retinal nerve fibre
layer (RNFL) thickness [13], which is an important OCT
marker for assessing the structural integrity of retinal
axons [14,15]. Likewise, functional acuity contrast test-
ing (FACT), as an alternative method for assessing low
contrast sensitivity, was shown to correlate well with ret-
inal axon damage in MS [16]. Consequently, clinician-
researchers have suggested including low contrast visual
acuity testing in the Multiple Sclerosis Functional Com-
posite (MSFC), the most widely used quantitative clinical
assessment tool in MS [9,17,18].
In order to better understand both the benefits and
the limitations of low contrast visual function testing,
further studies are needed to define their place in the
often complicated array of neurological symptoms in MS
patients. Sophisticated visual function tests have become
increasingly challenging and demanding for the patient.
For example, the identification of letters (e.g. Sloan and
Pelli-Robson charts) or the direction of grated lines
(FACT) most likely requires higher cognitive functions.
We therefore hypothesised that test performance is likely
not only influenced by visual impairment (in terms of
actual morphological damage to the anterior visual sys-
tem) but also by higher cognitive and executive functions.
Cognitive impairment (CI) is also a common symptom
in MS with a prevalence of about 50% [19] and mild
cognitive decline can even begin in early MS [20]. Pro-
cessing speed, working memory and executive function
are the cognitive domains mainly affected [19].
In light of this, our study sought to determine how
cognitive impairment influences low contrast sensitivity
testing. Here we report cross-sectional data from a large
prospective cohort of relapsing-remitting MS patients.
To assess morphological visual impairment we deter-
mined RNFL thickness [14]. Cognitive function was
assessed using Rao’s Brief Repeatable Battery of Neuro-
psychological Testing (BRB-N) [21].
Methods
Patients and study design
For this cross-section pilot study, eighty-nine patients
with RRMS according to the 2005 panel criteria [22]
were recruited from the outpatient clinic of the Clinical
and Experimental Multiple Sclerosis Research Center at
the Charité – Universitätsmedizin Berlin. Inclusioncriteria were: definite RRMS, Expanded Disability Status
Scale (EDSS) between 0.0 and 6.0, stable immune-
modulatory therapy for at least 6 months. Exclusion criteria
were: acute relapses and/or steroid treatment three months
prior to inclusion, any other ocular diseases with known
retinal pathology (i.e. glaucoma), refractive error > ±5 dpt.
There were no specific inclusion or exclusion criteria in re-
gard to cognitive or psychiatric status. Patients underwent
clinical assessment, neuropsychological testing and visual
examination within a three-month period. An overview of
the cohort’s demographic details is given in Table 1.
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the Charité – Universitätsmedizin Berlin and was con-
ducted in accordance with the Declaration of Helsinki in its
current version. All patients gave written informed consent.
Clinical examination and neuropsychological testing
All participants underwent clinical neurological examin-
ation, including the EDSS, under the supervision of a
board-certified neurologist [7]. Fatigue was assessed
using the Fatigue Severity Scale (FSS) [23]. Patient with
a mean FSS score > = 4 were classified as fatigued.
Depression was assessed using Beck’s Depression inven-
tory (BDI) [24]. Patients’ depression was classified using
the following cutoff-values: Minimal: 0 – 9; Mild: 10 – 18;
Moderate: 19 – 29; Severe: > = 30. The BDI was not avail-
able for two patients. Patients performed all subtests
of the German BRB-N version A under supervision of
trained examiners and with best available optic correction
[21,25]. Tests were performed as previously described in
detail [26]. Briefly, the BRB-N consists of the following
subtests: 1) Selective Reminding Testing (SRT)[27], which
measures verbal learning and memory in terms of imme-
diate recall (SRT-LTS and SRT-CLTR) and delayed recall
(SRT-D); 2) 10/36-Spatial Recall Testing [28], which mea-
sures the visio-spatial memory in terms of immediate re-
call (SPART) and delayed recall (SPART-D); 3) Symbol
Digit Modalities Testing (SDMT) [29], which tests infor-
mation processing speed and concentration; 4) Paced
Auditory Serial Addition Testing [30], including the three-
second version (PASAT3) and the two-second version
(PASAT2), which measures information-processing speed
and working memory; 5) Word List Generation (WLG)
[31], which tests semantic verbal fluency, verbal produc-
tion and executive function. BRB-N z-scores were calcu-
lated as previously described against normative data for
German MS patients using the original script kindly pro-
vided by Dr. Scherer [25]. Patients were classified as cog-
nitively impaired when z-score < 1.68 [25].
Visual acuity and contrast sensitivity
Visual acuity (VA) and contrast sensitivity (CS) were
analysed using the “Optec 6500 P vision testing system”
(Stereo Optical, Chicago, Illinois). A trained operator
performed all examinations in a darkened room. VA was
assessed in decimal fractions using Early Treatment Dia-
betic Retinopathy Study (ETDRS) charts. These results
were then summarised by translation into Snellen equiv-
alents. CS was measured using Functional Acuity Con-
trast Testing (FACT) and was performed monocularly
for both eyes with test scores as the last correct grating
determined under photopic conditions without glare. Pho-
topic conditions were simulated with 85 cd/m2 at target
image. FACT evaluation was performed by calculating the
Area Under the Log Contrast Sensitivity Function (AUC)as previously described in detail [16]. Briefly, the five con-
trast sensitivity values at five different spatial frequencies
for each measurement were transformed into logarithmic
expression and a curve combining all values using a poly-
nomial fit function was calculated. The AUC was then cal-
culated as the area between the lowest and highest spatial
frequency under this curve.
Optical coherence tomography
Optical coherence tomography was performed on both eyes
of each patient using a spectral domain OCT (SD-OCT)
device (Heidelberg Spectralis, Heidelberg Engineering,
Heidelberg, Germany) by experienced operators. Retinal
nerve fibre layer thickness (RNFL) was measured using
standard protocol with three 3.4 mm circular scans. All scans
were reviewed for scan quality according to [32]. The scan
with the highest quality or, if equal quality was achieved, an
arbitrarily selected one, was included in the analysis.
Statistical analysis
The correlation between visual and cognitive tests was
analysed using generalized estimating equations models
(GEE) to account for within-patient inter-eye effects.
Combined models using both RNFL and PASAT or
RNFL and SDMT as multiple independent variables and
CS as dependent variable were analysed using GEE. An
estimation of the partial correlation between cognitive
tests and visual tests controlled for RNFL was calculated
using the following approach: First, GEE analyses were
performed, with each parameter as dependent variable
and RNFL as independent variable in a normalized fash-
ion. The residuals from these models were then fed into
a Spearman’s Rho correlation analysis, producing results
comparable to those of a regular partial correlation ana-
lysis, but which also take into account within-subject
inter-eye effects. Local regression analysis (LOESS) was
used to visually estimate influence of cognitive impair-
ment on visual function testing [33]. All statistical ana-
lyses were performed using SPSS Statistics 20 (SPSS
Statistics Version 20, IBM, Armonk, NY, USA). A type I
error level of α = 0.05 was taken to indicate statistical
significance. All test results should be considered ex-
ploratory data analysis as no previous sample size calcu-
lation or adjustment for multiple testing was applied.
Results
Correlation between RNFL and visual and cognitive
performance
An overview of the OCT and visual function test results is
given in Table 1. A summary of the BRB-N scores is given
in Table 2. 28% of the patients were cognitively impaired
according to the BRB-N. We tested the possible correlation
between, firstly, RNFL thickness and visual test results and,
secondly, RNFL thickness and cognitive test results using
Table 2 Data from cognitive testing and correlation with visual test performance
GEE vs. CS Part. Corr. vs. VA Part. Corr. vs. CS
Mean SD Min Max B SE P Coefficient P Coefficient P
SRT-LTS 60 11 24 72 0.008 0.003 0.007 0.079 0.333 0.154 0.093
SRT-CLTR 55 15 4 72 0.004 0.003 0.103 0.081 0.319 0.160 0.080
SRT-D 11 2 2 12 0.057 0.021 0.008 0.188 0.021 0.336 <0.001
SPART 23 5 10 30 0.019 0.007 0.012 0.240 0.003 0.215 0.018
SPART-D 9 2 3 10 0.025 0.025 0.321 0.154 0.058 0.055 0.548
SDMT 56 12 32 85 0.010 0.002 <0.001 0.338 <0.001 0.343 <0.001
PASAT3 50 9 24 60 0.014 0.003 <0.001 0.171 0.035 0.286 <0.001
PASAT2 40 9 19 59 0.009 0.004 0.013 0.157 0.082 0.240 0.019
WLG 28 7 14 42 0.014 0.005 0.008 −0.056 0.496 0.221 0.016
BRB-N z 0.685 1.270 −4.084 2.715 0.083 0.029 0.004 0.142 0.083 0.249 0.006
Abbreviations: SRT-LTS selective reminding test long term storage, SRT-CLTR selective reminding test consistant long term retrieval, SRT-D selective reminding test
delayed recall, SPART spatial recall test, SPART-D spatial recall test delayed recall, PASAT paced auditory serial addition test, WLG word list generation, BRB-N brief
repeatable battery of neuropsychological tests, VA high contrast visual acuity, CS low contrast sensitivity.
Significant P values are printed in bold.
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high contrast VA (B = 0.011, SE = 0.002, p < 0.001) and CS
(B = 0.011, SE = 0.002, p < 0.001). In contrast, there was no
correlation between RNFL thickness and any of the BRB-N
tests (p ≥ 0.223).
Subsequently, we investigated whether visual function
testing correlated with cognitive test performance. Here,Figure 1 Local regression analysis of cognitive influence on low contr
B) Correlation between SDMT and CS. Grey lines are from LOESS analysis. H
LOESS lines represent areas with correlation between cognitive function an
separate the areas with an influence (left sides) and without influence (righ
layer thickness show a similar result (not shown). Abbreviations: LOESS, loc
auditory serial addition test three second version; SDMT, symbol digit mod
log contrast sensitivity function.CS correlated significantly with BRB-N z-scores and most
subtests, except SRT-CLTR and SPART-D (Table 2).
Correlation between contrast sensitivity and cognition
when controlling for RNFL
To determine whether the anterior visual system (i.e. ret-
inal damage) influences the correlations discussed above,ast sensitivity testing. A) Correlation between PASAT and CS,
orizontal LOESS lines represent areas with low or no correlation; rising
d visual function test performance. For better visibility dotted lines
t sides). Data from partial correlations controlling for retinal nerve fibre
al regression analysis; CS, low contrast sensitivity; PASAT, paced
alities test; FACT, functional acuity contrast testing; AUC, area under the
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function and cognitive function tests but controlling for
RNFL. This way, an influence of actual retinal damage to
the performance on visual tests should be eliminated.
When controlling for RNFL, a clear correlation was deter-
mined between VA and SRT-D, SPART, SDMT and
PASAT3. Likewise, CS correlated with the latter cognitive
tests, as well as with PASAT2 and WLG (Table 2). In the
involved domains, coefficients were moderate and roughly
twice as high for cognitive influence on CS as for cognitive
influence on VA with the exception of SDMT, a visually
dependent cognitive test. SDMT correlation with visual
function testing was highest among all tests with r = 0.34
both in CS and VA testing (Figure 1).
Cognitive function and RNFL together predict contrast
sensitivity
To determine whether retinal morphology and cognitive
function have an additive effect, we assessed the combined
effect of cognitive test performance and RNFL on visual
function testing. Detailed results are given in Table 3. In
summary, in a multiple GEE both PASAT and RNFL pre-
dicted CS. Similarly, both SDMT and RNFL correlated
with CS. BRB-N and all subtests except SRT-CLTR, SPAT-
D and WLG were also significantly predictive of CS.
Discussion
Our cross-sectional pilot study investigated the influence
of cognitive impairment on visual function testing in MS
patients. Our data show that a) cognitive impairment
correlates with performance in visual function tests such
as low contrast sensitivity testing; b) the main cognitiveTable 3 Results from combined GEE predicting low
contrast sensitivity test performance
Cognitive test RNFL average
B SE P B SE P
SRT-LTS 0.006 0.0028 0.024 0.011 0.0023 <0.001
SRT-CLTR 0.004 0.0022 0.064 0.011 0.0023 <0.001
SRT-D 0.047 0.0179 0.009 0.011 0.0024 <0.001
SPART 0.019 0.0077 0.015 0.011 0.0023 <0.001
SPART-D 0.026 0.0226 0.244 0.012 0.0024 <0.001
SDMT 0.007 0.0021 <0.001 0.001 0.0023 <0.001
PASAT3 0.012 0.0038 0.002 0.011 0.0025 <0.001
PASAT2 0.008 0.0039 0.035 0.001 0.0031 <0.001
WLG 0.009 0.0047 0.052 0.011 0.0024 <0.001
BRB-N z 0.003 0.0011 0.017 0.011 0.0023 <0.001
Abbreviations: SRT-LTS selective reminding test long term storage, SRT-CLTR
selective reminding test consistant long term retrieval, SRT-D selective
reminding test delayed recall, SPART spatial recall test, SPART-D spatial recall
test delayed recall, PASAT paced auditory serial addition test, WLG word list
generation, BRB-N brief repeatable battery of neuropsychological tests, RNFL
retinal nerve fiber layer thickness.
Significant P values are printed in bold.domains correlating with visual test performance are
information processing speed and, to a lesser degree,
memory.
When quantifying clinical symptoms in MS patients,
the examiner has to carefully consider bias from other
functional domains. For example, in cognitive testing,
motor impairment can impede the provision of a signal
by pressing a button, while visual impairment can ham-
per the recognition of figures or shapes. Overall, little
attention has been paid to the interplay between cogni-
tive and visual function and its potential influence on
clinical testing. Two previous investigations studying the
converse of our study focus were able to demonstrate
the validity of their hypothesis, namely, that visual acuity
indeed influences performance in visually dependent
cognitive tests like SDMT [34,35]. The authors’ conc-
lusion was that visual dysfunction potentially impairs
test performance in visually dependent cognitive tests.
Changes in cognitive function might therefore be over-
or underestimated when switching from non-visually
dependent tests like PASAT to visually dependent tests
like SDMT. Consequently, visual pre-screening is cur-
rently recommended when applying and interpreting
visually dependent cognitive test results [36].
But can on the other hand cognitive impairment influ-
ence visual function test results? A recent study investi-
gating auditory-based cognitive tests (i.e. PASAT) in
combination with low contrast visual acuity showed that
the latter correlates strongly with visually dependent but
also non-visually dependent cognitive test results [37].
However, crucially, the authors did not compare their
findings to actual damage to the visual pathway [13]. By
not factoring in morphological assessment such as by
RFNL thickness, the correlation between cognitive im-
pairment and visual function could simply have been a
correlate of overall disease progression with visual and
cognitive performance declining in parallel, yet inde-
pendently. This reservation is underlined by the results
of a study by Toledo and colleagues, which has shown
strong correlation between RNFL thickness and cogni-
tive impairment [38]. Our assessment of the relationship
between cognitive and visual test performance excised the
influence of optical morphological damage by including
RNFL thickness measurements in our analysis. As the cor-
relation between non-visually dependent cognitive test re-
sults and visual function tests remained intact, our results
provide evidence to support the hypothesis that cognitive
impairment influences visual test scores. Particularly our
investigation of the correlation between SDMTand VA in-
dicates that more demanding visual tests are affected by
cognitive impairment.
The main cognitive domain correlating with visual test
performance was speed of information processing, which
is a key domain keenly affected in MS [19]. Reduced
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ognized as one of the hallmark cognitive domains im-
paired in MS and is the basis for PASAT and SDMT
being used as screening tests for cognitive impairment
in MS, since both tests mainly assess this domain [36].
Studies have suggested that reduced processing speed
might be the result of alterations in participating neural
networks due to damaged white and grey matter [39].
Put simply, compared to health controls, MS patients
take more time to complete tasks in cognitive testing,
because they require greater neural recruitment [40].
Our results might be explained by the influence of simi-
lar neural network disruptions in cognitive domains
when processing visual tests, suggesting that investiga-
tion of neural recruitment also in higher cognitive do-
mains during low contrast visual acuity testing may well
prove a valuable avenue of further investigation.
Other studies have shown that changes in the atten-
tion network might also contribute to this reduction in
processing speed [41]. For example, Motoyoshi showed
in a recent study that diminishment of attention by in-
clusion of a concurrent task reduces CS for grating with
low temporal frequencies, and concluded that CS might
well be generally modulated by attention [42]. However,
this finding could be specific to the grating charts used
in our and also Motoyoshi’s study and might not apply
to letter-based low contrast acuity testing like that of the
Sloan test.
Caveats of our study include the lack of a healthy con-
trol group. As a result, our study cannot determine
whether the observed influence is disease specific (as the
focus on processing speed suggests) or performance spe-
cific (meaning that also healthy individuals with low cog-
nitive performance might show similar associations).
Additionally, our study included mostly patients with
mild or no cognitive impairment. A study investigating
patients with an on average higher cognitive and clinical
burden would allow more meaningful assessment of the
dimension of cognitive influence on visual test results
within a range of higher cognitive impairment. In this
regard it would be of interest, how our results relate
to general disease activity markers i.e. from magnetic
resonance imaging. Unfortunately these were not avail-
able for this cohort, which is another weakness of this
study. As a result, this study cannot answer the question,
how much of the reported effects might be based on
overall disease progression (i.e. both the visual and
cognitive systems progress in parallel but independently
of each other).
Furthermore, RNFL only represents a limited portion
of the visual pathway and results might not include
changes in areas such as the posterior visual pathway
[43] between the lateral geniculate corpora and the oc-
cipital cortex, caused not by optic neuritis (ON) [44],but by incidental lesions [45]. Thus, our correction
for RNFL may not have included the entirety of mor-
phological damage to the visual system in our study
participants. This could be addressed in a subsequent
study by employing e.g. visually evoked potentials
(VEP) to accurately define the influence of the visual
pathway on visual test performance using an alterna-
tive method [46].
Of note, some discrepancies exist between our study
and the study by Toledo et al. [38]. Although sample
size, disease severity and applied methods were compar-
able, Toledo and colleagues found a moderate correl-
ation between RNFL and cognitive impairment in
several cognitive domains, whereas our data did not
show this correlation. This is most likely explained by
the heterogeneity of the disease but should serve as a
reminder that our results should be confirmed in a dif-
ferent cohort.
Our findings are relevant both for clinical trials and
clinical practitioners. Visual and cognitive impairment
are key determinants of disease burden in MS, and
ascertaining the impairment of both is important in
the assessing of any new immunomodulatory or symp-
tomatic therapy [47]. Although the correlation between
cognitive and visual function in our study was only mod-
erate (less than 6% of CS test variance could be ex-
plained by cognitive dysfunction based on BRB-N, 12%
based on SDMT), the effect might prove highly relevant
in longitudinal observations, when changes in cognitive
function might manifest as changes in visual test perfor-
mances. For example, a reduction in cognitive perform-
ance could present as a change in visual function. Vice
versa, an improvement in cognitive function after an
acute relapse could also translate into improved visual
function test results [48]. When applying low contrast
sensitivity testing as outcome measure in clinical trials
[49], careful investigation of possible confounders from
cognitive impairment is therefore warranted. Of note,
the shown correlation between cognitive performance
and visual test results does not prove a causal relation-
ship. This cross-sectional pilot data has therefore only a
limited explanatory power. A longitudinal study is there-
fore currently underway.
Conclusion
In summary, our study shows that visual and cognitive
function are closely linked in MS. Specifically, cognitive
impairment might bias the results of challenging tasks
designed to assess visual acuity, such as those based on
low contrast visual acuity testing. This correlation is
not only a result of overall disease progression, but is
strongly dependent on both visual and cognitive func-
tion per se since the effect persisted after correcting for
actual morphological damage to the visual system.
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